About Quinnova Pharmaceuticals
Quinnova Pharmaceuticals is a company based in Newtown Square (United States) founded in 2003 by Jeffrey Day was acquired by Exeltis in December 2013.. Quinnova Pharmaceuticals has raised $31.32 million across 3 funding rounds from investors including Exeltis, Safeguard Scientifics and Thomas, McNerney & Partners. Quinnova Pharmaceuticals operates in a competitive market with competitors including Revance Therapeutics, Hugel, Dermavant, Sol-Gel Technologies and SkinMedica, among others.
- Headquarter Newtown Square, United States
- Founders Jeffrey Day
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Quinnova Pharmaceuticals
Quinnova Pharmaceuticals has successfully raised a total of $31.32M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $300 thousand completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $300,000
-
First Round
First Round
(28 Nov 2006)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2010 | Amount | Series B - Quinnova Pharmaceuticals | Valuation |
investors |
|
| Oct, 2009 | Amount | Series B - Quinnova Pharmaceuticals | Valuation | Safeguard Scientifics | |
| Nov, 2006 | Amount | Series A - Quinnova Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Quinnova Pharmaceuticals
Quinnova Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Exeltis, Safeguard Scientifics and Thomas, McNerney & Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in early and growth stage companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Quinnova Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Quinnova Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Quinnova Pharmaceuticals Comparisons
Competitors of Quinnova Pharmaceuticals
Quinnova Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Hugel, Dermavant, Sol-Gel Technologies and SkinMedica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Skin care products are developed and manufactured by SkinMedica.
|
|
| domain | founded_year | HQ Location |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Quinnova Pharmaceuticals
When was Quinnova Pharmaceuticals founded?
Quinnova Pharmaceuticals was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Where is Quinnova Pharmaceuticals located?
Quinnova Pharmaceuticals is headquartered in Newtown Square, United States. It is registered at Newtown Square, Pennsylvania, United States.
Who is the current CEO of Quinnova Pharmaceuticals?
Jeffrey Day is the current CEO of Quinnova Pharmaceuticals. They have also founded this company.
Is Quinnova Pharmaceuticals a funded company?
Quinnova Pharmaceuticals is a funded company, having raised a total of $31.32M across 3 funding rounds to date. The company's 1st funding round was a Series A of $13.6M, raised on Nov 28, 2006.
What does Quinnova Pharmaceuticals do?
Exeltis (formerly Quinnova Pharmaceuticals) is a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. Products include recedo topical gel for scars caused by injury and surgery, ecoza for interdigital tinea pedis, neosalus for atopic dermatitis, atrapro for burning and itching associated with dermatoses, salvax for hyperkeratotic skin disorders and hydro 35 foam for skin softening in hyperkeratoric disorders. Company got acquired by everett labs in 2013 for undisclosed amount.
Who are the top competitors of Quinnova Pharmaceuticals?
Quinnova Pharmaceuticals's top competitors include Revance Therapeutics, Dermavant and Collplant.
Who are Quinnova Pharmaceuticals's investors?
Quinnova Pharmaceuticals has 6 investors. Key investors include Exeltis, Safeguard Scientifics, Thomas, McNerney & Partners, HIG BioHealth Partners, and H.I.G. Capital.